<DOC>
	<DOCNO>NCT01508130</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety two approve pegylated interferon-based direct act antiviral triple therapy patient chronic hepatitis C genotype 1 . Patients receive pegylated interferon ( e.g . Pegasys ) ribavirin plus either telaprevir boceprivir accordance local standard care US labeling follow duration treatment 24 week post-treatment .</brief_summary>
	<brief_title>An Observational Study Peginterferon ( e.g . Pegasys ) -Based Direct Acting Antiviral Triple Therapy Patients With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic hepatitis C , genotype 1 Receiving pegylated interferonbased direct act antiviral therapy ( pegylated interferon ribavirin plus either telaprevir boceprivir ) accordance local standard care US label Contraindications per US label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>